Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTR1F | P30939 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494263 | 0.83 | KDM4E (0.58) | POLBKDM4EGAAMEN1KMT2A | |
| SCHEMBL28975833 | 0.83 | POLB (0.68) | POLBKDM4EGAAMEN1KMT2A | |
| SCHEMBL2552838 | 0.82 | HTR2A (0.62) | MEN1KMT2AHSD11B1MGLLHTR2A | |
| SCHEMBL21381589 | 0.81 | POLB (0.67) | POLBKDM4EGAAMEN1KMT2A | |
| SCHEMBL13391062 | 0.81 | SLC18A3 (0.63) | POLBKDM4EGAAHTR1FMEN1 | |
| SCHEMBL28203216 | 0.81 | KMT2A (0.71) | MEN1KMT2AHSD11B1MGLL | |
| SCHEMBL13944389 | 0.81 | SRD5A2 (0.57) | POLBHTR1FMEN1KMT2AHSD11B1 | |
| SCHEMBL28975834 | 0.80 | POLB (0.57) | POLBKDM4EGAAMEN1KMT2A | |
| SCHEMBL28187892 | 0.80 | POLB (0.53) | POLBKDM4EGAAMEN1KMT2A | |
| SCHEMBL28957256 | 0.80 | POLB (0.55) | POLBKDM4EGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | POLB 387/4885KDM4E 1664/4885GAA 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.